Sonnet Biotherapeutics Holdings Inc (SONN)

NASDAQ
Currency in USD
9.6400
+4.4700(+86.46%)
Closed·
After Hours
9.2800-0.3500(-3.6345%)
·
SONN Scorecard
Full Analysis
Analysts anticipate sales growth in the current year
Unusual trading volume
Fair Value
Day's Range
7.780019.3000
52 wk Range
1.080019.3000
Key Statistics
Edit
Prev. Close
9.64
Open
15.03
Day's Range
7.78-19.3
52 wk Range
1.08-19.3
Volume
44.62M
Average Volume (3m)
3.59M
1-Year Change
38.12%
Book Value / Share
0.22
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SONN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
20.0000
Upside
+107.47%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in overbought territory
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Sonnet Biotherapeutics Holdings Inc Company Profile

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 to treat chemotherapy-induced peripheral neuropathy (CIPN), and diabetic peripheral neuropathy; SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer; SON-1411, a bifunctional combination of human interleukin 18 (IL-18) inhibitor binding protein and single-chain human IL-12 (IL-12) for solid tumor cancers; and SON-1400, a monofunctional fusion protein comprising the IL-18 binding protein resistant domain linked to the FHAB. It has a license agreement with New Life Therapeutics Pte, Ltd. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.

Compare SONN to Peers and Sector

Metrics to compare
SONN
Peers
Sector
Relationship
P/E Ratio
−2.3x−4.0x−0.5x
PEG Ratio
−0.03−0.150.00
Price/Book
46.1x2.0x2.6x
Price / LTM Sales
30.5x10.5x3.2x
Upside (Analyst Target)
107.5%104.0%46.0%
Fair Value Upside
Unlock15.2%6.3%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 20.0000
(+107.47% Upside)

Earnings

Latest Release
May 13, 2025
EPS / Forecast
-0.89 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

SONN Income Statement

People Also Watch

18.5500
ARTL
-22.30%
2.420
MBIO
-8.68%
5.390
SQNS
+19.78%
8.070
NDRA
-0.37%
4.9800
CLRB
+2.05%

FAQ

What Is the Sonnet Biotherapeutics Holdings (SONN) Stock Price Today?

The Sonnet Biotherapeutics Holdings stock price today is 9.64

What Stock Exchange Does Sonnet Biotherapeutics Holdings Trade On?

Sonnet Biotherapeutics Holdings is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Sonnet Biotherapeutics Holdings?

The stock symbol for Sonnet Biotherapeutics Holdings is "SONN."

What Is the Sonnet Biotherapeutics Holdings Market Cap?

As of today, Sonnet Biotherapeutics Holdings market cap is 30.52M.

What Is Sonnet Biotherapeutics Holdings's Earnings Per Share (TTM)?

The Sonnet Biotherapeutics Holdings EPS (TTM) is -7.09.

From a Technical Analysis Perspective, Is SONN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Sonnet Biotherapeutics Holdings Stock Split?

Sonnet Biotherapeutics Holdings has split 8 times.

How Many Employees Does Sonnet Biotherapeutics Holdings Have?

Sonnet Biotherapeutics Holdings has 13 employees.

What is the current trading status of Sonnet Biotherapeutics Holdings (SONN)?

As of Jul 15, 2025, Sonnet Biotherapeutics Holdings (SONN) is trading at a price of 9.64, with a previous close of 9.64. The stock has fluctuated within a day range of 7.78 to 19.30, while its 52-week range spans from 1.08 to 19.30.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.